Literature DB >> 15569996

HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression.

Gennaro Chiappetta1, Gerardo Botti, Mario Monaco, Rosa Pasquinelli, Francesca Pentimalli, Maurizio Di Bonito, Giuseppe D'Aiuto, Monica Fedele, Rodolfo Iuliano, Emiliano A Palmieri, Giovanna Maria Pierantoni, Vincenzo Giancotti, Alfredo Fusco.   

Abstract

We measured, by immunohistochemistry, HMGA1 protein expression in 212 breast tissue specimens: 6 normal samples, 28 hyperplastic lesions (13 with cellular atypia), 11 fibroadenomas, 10 in situ ductal carcinomas, 144 ductal carcinomas, and 13 lobular carcinomas. HMGA1 was not expressed in normal breast tissue; HMGA1 staining was intense in 40% of hyperplastic lesions with cellular atypia and in 60% of ductal carcinomas and weak in fibroadenomas and in hyperplastic lesions without cellular atypia. Because HMGA1 expression was similar among ductal breast carcinomas with different histologic grading, we evaluated the association between HMGA1 expression and that of other markers of breast carcinoma invasion (estrogen and progesterone receptors, Ki-67 antigen, and ErbB2) in 21 cases of grade 3 breast ductal carcinomas and 7 cases of breast lobular carcinomas. We found that HMGA1 expression tended to be associated only with c-erbB-2 expression (Spearman rho: 0.36; P=0.065). Taken together, these results suggest that HMGA1 expression might be a novel indicator for the diagnosis and prognosis of human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15569996     DOI: 10.1158/1078-0432.CCR-04-0291

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  35 in total

1.  Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.

Authors:  Siong-Seng Liau; Stanley W Ashley; Edward E Whang
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

Review 2.  High mobility group proteins and their post-translational modifications.

Authors:  Qingchun Zhang; Yinsheng Wang
Journal:  Biochim Biophys Acta       Date:  2008-05-10

Review 3.  High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.

Authors:  S S Liau; E Whang
Journal:  Surgeon       Date:  2009-10       Impact factor: 2.392

4.  HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesis.

Authors:  Bo Pang; Haitao Fan; Ian Y Zhang; Bin Liu; Bin Feng; Lei Meng; Rui Zhang; Sam Sadeghi; Hua Guo; Qi Pang
Journal:  J Neurooncol       Date:  2011-10-08       Impact factor: 4.130

Review 5.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

6.  Elevated expression of HMGA1 correlates with the malignant status and prognosis of non-small cell lung cancer.

Authors:  Ze Zhang; Quan Wang; Feng Chen; Jun Liu
Journal:  Tumour Biol       Date:  2014-10-25

7.  Knockdown of HMGA1 inhibits human breast cancer cell growth and metastasis in immunodeficient mice.

Authors:  Francescopaolo Di Cello; James Shin; Kirsten Harbom; Cory Brayton
Journal:  Biochem Biophys Res Commun       Date:  2013-03-29       Impact factor: 3.575

8.  Identification of candidate cancer genes involved in human retinoblastoma by data mining.

Authors:  Juhua Yang; Jian-Jun Zhao; Yihua Zhu; Wei Xiong; Jian-Yin Lin; Xu Ma
Journal:  Childs Nerv Syst       Date:  2008-03-19       Impact factor: 1.475

9.  High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma.

Authors:  Siong-Seng Liau; Flavio Rocha; Evan Matros; Mark Redston; Edward Whang
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

10.  HMGA1a recognition candidate DNA sequences in humans.

Authors:  Takayuki Manabe; Taiichi Katayama; Masaya Tohyama
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.